Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Heymann

Showing results (81-90 of 243) with videos related to

Pageof 25
Sort By:
Journal of Cellular Physiology|January 12, 2018
Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do?Jorge W Vargas-Franco, Beatriz Castaneda, Françoise Rédiní, et al.
Cancer Letters|September 13, 2021
The intratumoral microbiome: Characterization methods and functional impactClément J F Heymann, Jean-Marie Bard, Marie-Françoise Heymann, et al.
Oncotarget|August 4, 2016
miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumorsCamille Jacques, Lidia Rodriguez Calleja, Marc Baud'huin, et al.
Cancer Letters|May 27, 2018
Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcomaYolanda González-Fernández, Hannah K Brown, Ana Patiño-García, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2012
Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcomaElisabeth Miot-Noirault, François Gouin, Marie-Mélanie Dauplat, et al.
American Journal of Cancer Research|May 7, 2016
L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transferKevin Biteau, Romain Guiho, Mathias Chatelais, et al.
Nature Reviews. Clinical Oncology|September 25, 2023
Drug-tolerant persister cells in cancer: the cutting edges and future directionsYi Pu, Lu Li, Haoning Peng, et al.
Expert Opinion on Emerging Drugs|August 21, 2013
Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Francoise Redini, Guillaume A Odri, Gaëlle Picarda, et al.
Plos One|March 7, 2014
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine modelsBérengère Gobin, Gatien Moriceau, Benjamin Ory, et al.
Journal of Bone Oncology|June 1, 2018
Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitationsCamille Jacques, Nathalie Renema, Frederic Lezot, et al.
Pageof 25

Showing results (81-90 of 243) with videos related to

Sort By:
Pageof 25
Journal of Cellular Physiology|January 12, 2018
Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do?Jorge W Vargas-Franco, Beatriz Castaneda, Françoise Rédiní, et al.
Cancer Letters|September 13, 2021
The intratumoral microbiome: Characterization methods and functional impactClément J F Heymann, Jean-Marie Bard, Marie-Françoise Heymann, et al.
Oncotarget|August 4, 2016
miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumorsCamille Jacques, Lidia Rodriguez Calleja, Marc Baud'huin, et al.
Cancer Letters|May 27, 2018
Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcomaYolanda González-Fernández, Hannah K Brown, Ana Patiño-García, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2012
Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcomaElisabeth Miot-Noirault, François Gouin, Marie-Mélanie Dauplat, et al.
American Journal of Cancer Research|May 7, 2016
L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transferKevin Biteau, Romain Guiho, Mathias Chatelais, et al.
Nature Reviews. Clinical Oncology|September 25, 2023
Drug-tolerant persister cells in cancer: the cutting edges and future directionsYi Pu, Lu Li, Haoning Peng, et al.
Expert Opinion on Emerging Drugs|August 21, 2013
Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Francoise Redini, Guillaume A Odri, Gaëlle Picarda, et al.
Plos One|March 7, 2014
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine modelsBérengère Gobin, Gatien Moriceau, Benjamin Ory, et al.
Journal of Bone Oncology|June 1, 2018
Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitationsCamille Jacques, Nathalie Renema, Frederic Lezot, et al.
Pageof 25